Achillion Pharmaceuticals Inc (ACHN.O) Key Developments | Reuters.com
Edition:
United States

Achillion Pharmaceuticals Inc (ACHN.O)

ACHN.O on Nasdaq

8.06USD
24 Jun 2016
Change (% chg)

$-0.65 (-7.46%)
Prev Close
$8.71
Open
$8.10
Day's High
$8.44
Day's Low
$8.04
Volume
1,628,047
Avg. Vol
1,528,706
52-wk High
$10.95
52-wk Low
$5.57

Latest Key Developments (Source: Significant Developments)

Achillion presents interim phase 1 results for ACH-4471
Friday, 10 Jun 2016 03:30am EDT 

Achillion says : Presents interim phase 1 results for ACH-4471, a novel orally-administered factor D inhibitor . Results indicate up to 100% inhibition of alternative-pathway activity in hemolysis and Wieslab assays after oral dosing of ACH-447 .Results support initiation of phase 1 trial during q2 and phase 2 studies for PNH and C3G by year-end 2016.  Full Article

Achillion Pharmaceuticals Inc reaffirms FY 2015 revenue guidance; raises FY 2015 EPS guidance
Thursday, 5 Nov 2015 04:05pm EST 

Achillion Pharmaceuticals Inc:Expects FY 2015 total annual revenue to be $66 million, representing the total premium paid by JJDC associated with its equity purchase of Achillion common stock.Expects FY 2015 net loss per share to be approximately $0.08 - 0.10 per share.FY 2015 EPS of $(0.28) - Thomson Reuters I/B/E/S.  Full Article

Achillion Pharmaceuticals Inc reports 100% svr12 from second cohort of patients
Thursday, 17 Sep 2015 06:05am EDT 

Achillion Pharmaceuticals Inc:Reports 100% svr12 from second cohort of patients in the previously-completed six week phase 2 trial evaluating odalasvir (ach-3102) and sofosbuvir for genotype 1 hcv.Says 100% svr12 reported for all patients treated for six- (n=18) or eight-weeks.Odalasvir,sofosbuvir well tolerated with no significant adverse events, ecg findings, or lab abnormalities observed during treatment.Says announced additional interim results from a phase 2 study evaluating odalasvir (also known as ach-3102).  Full Article

Achillion Pharmaceuticals Inc gives FY 2015 guidance
Monday, 10 Aug 2015 06:05am EDT 

Achillion Pharmaceuticals Inc:Sees FY 2015 revenue to be $66 million.Sees FY 2015 net loss per share to be about $0.15 per share.  Full Article

Achillion Pharmaceuticals Inc announces closing of public offering of common stock
Wednesday, 18 Feb 2015 04:30pm EST 

Achillion Pharmaceuticals Inc:Closes public offering of common stock.Sold 13,800,000 shares of its common stock in the offering at a price to the public of $10.25 per share, including the exercise in full by the underwriters of their option to purchase an additional 1,800,000 shares of common stock at the public offering price.Received net proceeds of about $132.7 mln, after deducting underwriting discounts and commissions and estimated offering expenses.Leerink Partners LLC and Deutsche Bank Securities Inc. acted as joint book-running managers, Wells Fargo Securities, LLC acted as lead manager, and JMP Securities LLC acted as co-manager for the offering.  Full Article

Achillion Pharmaceuticals Inc announces pricing of public offering of common stock
Wednesday, 11 Feb 2015 11:59pm EST 

Achillion Pharmaceuticals Inc:Announced the pricing of an underwritten public offering of 12,000,000 shares of its common stock at a price to the public of $10.25 per share.All of the shares in the offering will be sold by Achillion.The net proceeds to Achillion from the sale of the shares, after deducting underwriting discounts and commissions and estimated offering expenses, are expected to be about $115.3 million.The offering is expected to close on Feb. 18, 2015.Leerink Partners LLC and Deutsche Bank Securities Inc. are acting as joint book-running managers, Wells Fargo Securities, LLC is acting as lead manager, and JMP Securities LLC is acting as co-manager for the offering.Achillion has granted the underwriters a 30-day option to purchase up to an additional 1,800,000 shares of its common stock on the same terms and conditions.The expected net proceeds to Achillion referenced above do not include any net proceeds that Achillion would receive if the underwriters exercise such option.  Full Article

Achillion Pharmaceuticals Inc announces proposed public offering of common stock
Tuesday, 10 Feb 2015 04:05pm EST 

Achillion Pharmaceuticals Inc:Commences underwritten public offering of 10,000,000 shares of its common stock.In connection with this offering, Achillion plans to grant the underwriters a 30-day option to purchase additional shares of its common stock.All of the shares in the offering will be sold by Achillion.Leerink Partners LLC and Deutsche Bank Securities Inc. are acting as joint book-running managers for the offering.Offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.  Full Article

Achillion Pharmaceuticals Inc achieves 100 pct SVR12 in Phase 2 Trial Evaluating 6-Week Combination Treatment With ACH-3102
Monday, 9 Feb 2015 06:30am EST 

Achillion Pharmaceuticals Inc:Updated interim results from the ongoing interferon-free, ribavirin-free, Phase 2 study to evaluate the efficacy, safety, and tolerability of six weeks of 50 mg of ACH-3102 and 400 mg of sofosbuvir, a marketed nucleotide polymerase inhibitor, in treatment-naïve genotype 1 HCV-infected patients.Says primary objective of the study is determination of sustained viral response 12 weeks (SVR12) after completion of therapy. One hundred percent of patients (12/12) in the six-week treatment duration arm achieved SVR12, which included patients with high baseline viral load.Says following the achievement of 100 pct SVR12 (12/12) in the eight-week cohort, the six-week treatment cohort was initiated.Says twelve weeks after the completion of therapy, 100 percent (12/12) achieved SVR12, independent of baseline viral load, gender, and IL28B status, in the six-week treatment arm.Says the combination of ACH-3102 and sofosbuvir was well-tolerated with no serious adverse events, no discontinuations due to adverse events, and no clinically significant laboratory or ECG abnormalities.  Full Article

Achillion granted U.S. patent for ACH-3102 and Structurally Related NS5A Inhibitors
Tuesday, 19 Aug 2014 04:05pm EDT 

Achillion Pharmaceuticals Inc:Announces that the U.S. Patent & Trademark Office has granted Achillion U.S. Patent No. 8,809,313, covering composition-of-matter and method of use claims for ACH-3102 and structurally related NS5A inhibitor compounds.  Full Article

Achillion Pharmaceuticals Inc achieves 100 pct sustained virologic response rate from an eight week phase 2 trial
Friday, 15 Aug 2014 06:59am EDT 

Achillion Pharmaceuticals Inc:Says interim results from ongoing Phase 2 proxy study evaluating ACH-3102, Achillion's second-generation NS5A inhibitor, in combination with sofosbuvir, without ribavirin, for eight weeks of treatment in patients with treatment-naïve genotype 1 chronic hepatitis C virus (HCV) infection.Says of the 12 patients treated, 100 percent (n=12/12) remained HCV RNA undetectable four weeks after completing therapy (SVR4).Says based upon these results, 12 additional patients will begin treatment with six weeks of once daily ACH-3102 and sofosbuvir.Says ACH-3102 continues to demonstrate good safety and tolerability through three Phase 2 studies.Says primary objective of the study is determination of sustained viral response 12 weeks (SVR12) after the completion of therapy\.Says Twelve patients completed eight weeks of treatment consisting of 50 mg of ACH-3102 and 400 mg of sofosbuvir administered once daily while observational patients received no drug during this phase of the trial.Says Ten of 12 patients receiving eight weeks of treatment had genotype 1a HCV with median HCV RNA at baseline of 7.22 log10(range 5.5 - 7.8 log10).Says no on-treatment viral breakthrough or post-treatment viral relapse has been observed to date.Says ACH-3102 and sofosbuvir were well tolerated with no significant adverse events, ECG findings, or lab abnormalities observed during treatment.  Full Article

BRIEF-Achillion reports Q1 loss per share $0.13

* Achillion reports first quarter 2016 financial results and provides update on clinical programs